Scinovex
articleTop 1% cited

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

The Lancet Oncology · 2015 · Vol. 16(9) · pp. 1090–1098
Joël ShapiroJ. Jan B. van LanschotMaarten C.C.M. HulshofPieter van HagenMark I. van Berge HenegouwenBas P. L. WijnhovenHanneke W.M. van LaarhovenGrard A. P. NieuwenhuijzenGeke A.P. HospersJohannes J. BonenkampMiguel A. CuestaR.J.B. BlaisseOlivier R. BuschFiebo J.W. ten KateGeert-Jan CreemersCornelis J.A. PuntJohn Th. M. PlukkerHenk M.W. VerheulErnst Jan Spillenaar BilgenHerman van DekkenMaurice J.C. van der SangenTom RozemaKatharina BiermannJannet C. BeukemaAnna H.M. PietCaroline M. van RijJanny G. ReindersHugo W. TilanusEwout W. SteyerbergAte van der Gaast
Esophageal Cancer Research and TreatmentGastric Cancer Management and OutcomesEsophageal and GI PathologyMedicineChemoradiotherapyCarboplatinSurgeryClinical endpointRadiation therapyCancerAdenocarcinomaClinical trialStage (stratigraphy)

MeSH terms

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophagogastric JunctionFemaleFluorouracilHumansMaleMiddle AgedNeoplasm StagingCarboplatinPaclitaxelDisease-Free SurvivalKaplan-Meier Estimate
Citations
2,497
FWCI
147.82
field-weighted impact
References
25
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.